Patient Square Capital’s Roivant Sciences ROIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $141M | Hold |
12,480,000
| – | – | 50.71% | 1 |
|
|
2025
Q1 | $126M | Hold |
12,480,000
| – | – | 52.09% | 1 |
|
|
2024
Q4 | $148M | Buy |
12,480,000
+251,535
| +2% | +$2.98M | 55.22% | 1 |
|
|
2024
Q3 | $141M | Hold |
12,228,465
| – | – | 52.38% | 1 |
|
|
2024
Q2 | $129M | Hold |
12,228,465
| – | – | 59.99% | 1 |
|
|
2024
Q1 | $129M | Sell |
12,228,465
-411,455
| -3% | -$4.34M | 54.89% | 1 |
|
|
2023
Q4 | $142M | Hold |
12,639,920
| – | – | 77.6% | 1 |
|
|
2023
Q3 | $148M | Hold |
12,639,920
| – | – | 81.13% | 1 |
|
|
2023
Q2 | $127M | Buy |
12,639,920
+5,813,953
| +85% | +$58.6M | 62.03% | 1 |
|
|
2023
Q1 | $50.4M | Hold |
6,825,967
| – | – | 40.49% | 2 |
|
|
2022
Q4 | $54.5M | Buy |
+6,825,967
| New | +$54.5M | 23.06% | 2 |
|